| Title |
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, December 2006
|
| DOI | 10.1007/s00280-006-0393-4 |
| Pubmed ID | |
| Authors |
Yong S. Chang, Jalila Adnane, Pamela A. Trail, Joan Levy, Arris Henderson, Dahai Xue, Elizabeth Bortolon, Marina Ichetovkin, Charles Chen, Angela McNabola, Dean Wilkie, Christopher A. Carter, Ian C. A. Taylor, Mark Lynch, Scott Wilhelm |
| Abstract |
New research findings have revealed a key role for vascular endothelial growth factor (VEGF) in the stimulation of angiogenesis in clear cell renal carcinoma (RCC) which is a highly vascularized and treatment-resistant tumor. Sorafenib (BAY 43-9006, Nexavar) is a multi-kinase inhibitor which targets receptor tyrosine and serine/threonine kinases involved in tumor progression and tumor angiogenesis. The effect of sorafenib on tumor growth and tumor histology was assessed in both ectopic and orthotopic mouse models of RCC. |
Mendeley readers
The data shown below were compiled from readership statistics for 169 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 1% |
| Australia | 1 | <1% |
| Unknown | 166 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 29 | 17% |
| Student > Ph. D. Student | 24 | 14% |
| Student > Master | 24 | 14% |
| Student > Bachelor | 16 | 9% |
| Student > Doctoral Student | 13 | 8% |
| Other | 28 | 17% |
| Unknown | 35 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 44 | 26% |
| Biochemistry, Genetics and Molecular Biology | 28 | 17% |
| Agricultural and Biological Sciences | 25 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 7% |
| Chemistry | 5 | 3% |
| Other | 12 | 7% |
| Unknown | 43 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 March 2022.
All research outputs
#2,860,542
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#92
of 2,501 outputs
Outputs of similar age
#10,598
of 159,586 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#2
of 11 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 159,586 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.